---
title: "NeuroSense plans PrimeC new drug filing with Health Canada for ALS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293473713.md"
description: "NeuroSense Therapeutics plans to file a New Drug Submission with Health Canada for PrimeC to treat ALS, following a Pre-NDS meeting. The submission includes Phase 2b PARADIGM data demonstrating a 14.9-month median survival benefit (HR 0.35, p=0.0037)."
datetime: "2026-07-22T12:31:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293473713.md)
  - [en](https://longbridge.com/en/news/293473713.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293473713.md)
generator: "portal-rs"
---

# NeuroSense plans PrimeC new drug filing with Health Canada for ALS

-   NeuroSense plans to file a New Drug Submission with Health Canada for PrimeC to treat ALS following a Pre-NDS meeting. \* The submission package includes Phase 2b PARADIGM data showing a 14.9-month median survival benefit (HR 0.35, p=0.0037). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607220830PR\_NEWS\_USPR\_\_\_\_\_LN09247) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NRSN.US](https://longbridge.com/en/quote/NRSN.US.md)
- [NRSNW.US](https://longbridge.com/en/quote/NRSNW.US.md)

## Related News & Research

- [11:29 ETNeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada](https://longbridge.com/en/news/295124860.md)
- [NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans](https://longbridge.com/en/news/295817302.md)
- [H.U. Group unit Fujirebio wins Health Canada licenses for Lumipulse neurology blood tests](https://longbridge.com/en/news/297597814.md)
- [US FDA is working with manufacturers to boost estradiol patch supply amid access concerns](https://longbridge.com/en/news/297917790.md)
- [Endovia plans FDA pre-submission conference for CannEpil Z filing](https://longbridge.com/en/news/297517810.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**